TY -的T1 -叶切除术应该保持第一个choice for treating early stage nonsmall cell lung cancer JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00649-2019 VL - 54 IS - 1 SP - 1900649 AU - Deng, Han-Yu AU - Zhou, Qinghua Y1 - 2019/07/01 UR - //www.qdcxjkg.com/content/54/1/1900649.abstract N2 - Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy, is characterised as a highly noninvasive precise radiotherapy that is performed by applying an external focused beam guided by high-resolution imaging to target well-defined small tumours [1]. Because of its high local control and survival with acceptable toxicity, SBRT has become the guideline-recommended choice for treating early stage nonsmall cell lung cancer (NSCLC) patients who are not fit for surgery [2]. However, recently, SBRT has also imposed great challenges to surgery in treating operable patients with early stage NSCLC [3]. However, in the absence of completed randomised controlled trials, the currently available evidence for comparing the efficacy of SBRT and surgery for treating early stage NSCLC has all come from observational studies with propensity score-matched analysis [4]. A recent study by Detillon et al. [5] has compared the efficacy of SBRT with video-assisted thoracoscopic (VATS) lobectomy for treating stage I NSCLC in elderly patients by applying propensity score-matched analysis. They included a total of 792 elderly patients (≥65 years old) with clinical stage I NSCLC undergoing SBRT or VATS lobectomy. In the analysis of unmatched cohorts, with significant baseline characteristics imbalance between the two groups, they found that VATS lobectomy yielded significantly better overall survival than SBRT (77 months versus 38 months; p<0.001). In the analysis of matched cohorts, with well-balanced characteristics between the two groups, VATS lobectomy yielded similar overall survival to SBRT in the first 15 months of follow-up, but significantly better overall survival than SBRT after 15 months of follow-up in both primary and secondary analyses with different matching covariates [5]. Therefore, their study again added to the evidence that patients with clinical stage I NSCLC receiving VATS lobectomy had better overall survival than patients receiving SBRT.Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer http://bit.ly/2M982Il ER -